NCT02907021View on ClinicalTrials.gov

Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

April 12, 2018

Study Completion Date

April 12, 2018

Conditions
Heart FailureBreast Cancer
Interventions
DRUG

standard-of-care treatments for LV impairment

Treat patients with mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers

Trial Locations (1)

L8V 1C3

Juravinski Hospital, Hamilton

Sponsors
All Listed Sponsors
lead

Population Health Research Institute

OTHER

NCT02907021 - Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2 | Biotech Hunter | Biotech Hunter